MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
7.00
-0.39
-5.28%
After Hours: 6.99 -0.01 -0.10% 17:33 05/13 EDT
OPEN
7.47
PREV CLOSE
7.39
HIGH
7.56
LOW
6.96
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
4.790
MARKET CAP
1.12B
P/E (TTM)
-6.0949
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OCUL last week (0505-0509)?
Weekly Report · 1d ago
Analyst Expectations For Ocular Therapeutix's Future
Benzinga · 05/06 12:01
RBC Capital Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
TipRanks · 05/06 11:23
Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank
TipRanks · 05/06 11:19
Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges
TipRanks · 05/06 10:25
Ocular Therapeutix Is Maintained at Buy by Needham
Dow Jones · 05/06 09:40
Ocular Therapeutix Advances in Retinal Treatment Trials
TipRanks · 05/06 04:01
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
Benzinga · 05/05 20:07
More
About OCUL
More
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
Recently
Symbol
Price
%Change
    PED
  • 0.5600
  • +5.56%

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.